Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Trainer-operators from ICTSI South Pacific’s Lae terminal in Papua New Guinea have provided MHC operations training to Filipino personnel at the Mindanao Container Terminal (MCT).